Oncology/Hematology
Lymphoma
More in Lymphoma
77% of pregnancies resulted in live births
News, features, and commentary about cancer-related issues
Durable response possible with treatment targeting a different antigen
R-CHOP plus venetoclax falls short, while R-CHOP with HDAC inhibitor shows promise
Incidence significantly reduced with two types of exercises versus usual care
News, features, and commentary about cancer-related issues
Our panel of experts discusses mosunetuzumab/polatuzumab vedotin for relapsed/refractory patients
News, features, and commentary about cancer-related issues
Granted accelerated approval last year, bispecific antibody passes its confirmatory test
High-rate of durable responses with ViPOR sparks talk of supplanting CAR-T in second line
Will 2-year DFS of 88%, OS of 96% renew interest in checkpoint inhibitor consolidation?
News, features, and commentary about cancer-related issues
Co-mutations, viral link, potential common susceptibility emerge from two studies
Second-gen ALK inhibitor induces high response rate, associated with impressive survival
